Corteva Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 5/6
Corteva şirketinin toplam hissedar öz sermayesi $25.4B ve toplam borcu $4.9B olup, bu da borç-öz sermaye oranını 19.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $41.6B ve $16.2B dir. Corteva 'in FAVÖK'ü $3.0B faiz karşılama oranı 74 dur. Şirketin $2.4B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.
Anahtar bilgiler
19.19%
Borç/özkaynak oranı
US$4.88b
Borç
| Faiz karşılama oranı | 74x |
| Nakit | US$2.37b |
| Eşitlik | US$25.40b |
| Toplam yükümlülükler | US$16.24b |
| Toplam varlıklar | US$41.64b |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Anlatı Güncellemesi • Aug 04
CTVA: Upcoming Seed Spinoff And Crop Protection Pipeline Will Reshape Earnings Mix
Analysts lifted their price target for Corteva to $92.40 from $90.05, pointing to updated expectations around the Vylor seed spinoff, the crop protection and fertilizer backdrop, and the revised P/E and profitability assumptions cited in recent research. Analyst Commentary Recent research on Corteva centers on how the Vylor seed spinoff, crop protection trends, and fertilizer market conditions may affect valuation, growth prospects, and execution risk.Seeking Alpha • Jul 31
Corteva: Strong Fundamentals, Limited Upside
Summary Corteva, Inc. stands as a global leader in pure agri-tech, emphasizing R&D for advanced seed genetics and sustainable crop solutions. My prior Hold ratings on CTVA underestimated the market's preference for quality, execution, and improved business visibility over strict valuation metrics. CTVA has significantly outperformed the broader market by four times and its ETF peers by more than two times since my earlier reviews. The investment thesis now centers on CTVA's superior execution and enhanced operational visibility as key drivers of its recent outperformance. Read the full article on Seeking AlphaAnaliz Makalesi • Jun 20
Corteva (CTVA) Stock Could Be 13% Undervalued After FMC Herbicide Deal
Why the new FMC partnership matters for Corteva stock Corteva (CTVA) recently signed a multi-year, co-exclusive supply and license agreement with FMC Corporation for rimisoxafen herbicide technology, giving the company another tool in corn and soybean crop protection. The deal covers North and South American markets, includes a US$200 million prepurchase payment from Corteva, and allows both companies to create their own premix formulations. Commercial sales are targeted by the end of the...Anlatı Güncellemesi • Jun 14
CTVA: Upcoming Spin Focused On Seed And Crop Protection Will Reshape Earnings Mix
Corteva's updated analyst price target edges higher by about $0.14 to roughly $90.05, as analysts refine their assumptions around revenue growth, profit margins and future P/E in light of recent target increases across the Street for the upcoming spin focused on seed and crop protection businesses. Analyst Commentary Recent research updates around Corteva cluster around the upcoming spin of its seed and crop protection businesses, with a series of higher price targets reflecting refreshed views on growth, execution and valuation for what some refer to as "New Corteva." Bullish analysts point to recalibrated assumptions on revenue, margins and P/E, while more cautious voices focus on whether the standalone company can consistently deliver against those expectations once separated.Anlatı Güncellemesi • May 31
CTVA: SpinCo Separation And Biofungicide Collaboration Will Reshape Future Earnings Mix
The analyst price target for Corteva is updated to $89.90 from $86.05 as analysts note that the market is treating "New Corteva" like a no-growth commodity chemical company. They instead highlight expectations for a healthier standalone growth profile, modestly higher profit margins, and a slightly lower assumed future P/E multiple.Analiz Makalesi • May 14
Corteva's (NYSE:CTVA) Performance Is Even Better Than Its Earnings Suggest
Even though Corteva, Inc.'s ( NYSE:CTVA ) recent earnings release was robust, the market didn't seem to notice...Anlatı Güncellemesi • Apr 27
CTVA: Fair Value View Weighs Crop Protection Uncertainty And Planned SpinCo Separation
Corteva's analyst price target has increased by about $2, as analysts cite updated earnings models, a revised fair value of $86.05, a slightly adjusted discount rate, and modest changes to revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Street research on Corteva has been active, with several price target revisions and a mix of ratings changes that give you both supportive and cautious signals to weigh.Anlatı Güncellemesi • Apr 13
CTVA: Fair Value View Balances Crop Protection Risks And Upcoming SpinCo Separation
The analyst price target for Corteva has moved modestly higher to align with a fair value estimate of about $84, as analysts factor in updated earnings models, slightly adjusted revenue growth and profit margin assumptions, and recent price target changes across several firms. Analyst Commentary Recent Street research on Corteva shows a mix of higher price targets and a few rating downgrades, so you are seeing both optimism and caution reflected in the current analyst debate.Anlatı Güncellemesi • Mar 28
CTVA: Crop Protection Uncertainty And SpinCo Separation Will Shape Future Risk Balance
The analyst price target for Corteva has been nudged higher, with a modest fair value uplift to $83.95 as analysts balance a series of recent target increases from multiple firms against more cautious views tied to softer crop protection trends. Analyst Commentary Recent research on Corteva reflects a split view, with several firms lifting price targets while others turn more cautious on near term fundamentals, especially in crop protection.Anlatı Güncellemesi • Mar 12
CTVA: Mixed Crop Protection Outlook And New SpinCo Plan Will Shape Risk Balance
The analyst price target for Corteva edges higher to $83.33 from $82.76, as analysts factor in slightly firmer long term revenue growth and profit margins, while balancing more cautious views on crop protection trends and a modestly lower discount rate. Analyst Commentary Recent research on Corteva reflects a split view, with several firms lifting price targets while others turn more cautious on execution in crop protection.Anlatı Güncellemesi • Feb 26
CTVA: Sector Uncertainty And New Ventures Will Shape Forward Risk Balance
Corteva's analyst fair value estimate has edged up to $82.76 from $82.05 as analysts refine their models and price targets following recent earnings updates and a broad wave of upward target revisions across the Street. Analyst Commentary Recent Street research around Corteva reflects an active debate, with several firms adjusting price targets and a mix of upgrades and downgrades around the latest earnings update.Anlatı Güncellemesi • Feb 11
CTVA: Mixed Sector Backdrop And New Ventures Will Shape Future Prospects
Corteva's analyst fair value estimate has increased to $82.05 from $78.43 as analysts factor in slightly stronger revenue growth assumptions, a higher future P/E multiple, and a modestly lower discount rate, even as projected profit margins are trimmed. Analyst Commentary Recent Street research on Corteva is mixed, with several bullish analysts lifting price targets while a few high profile firms turn more cautious.Anlatı Güncellemesi • Jan 26
CTVA: Seed And Crop Protection Split Will Shape Balanced Future Prospects
Narrative Update Analysts have modestly raised their price expectations for Corteva, with the updated fair value estimate moving by about US$0.48 per share. This reflects slightly adjusted assumptions for discount rate, revenue growth, profit margin, and future P/E, and is supported by recent target increases from several firms.Anlatı Güncellemesi • Jan 11
CTVA: Planned Seed And Pesticide Split Will Support Future Earnings Power
Analysts lifted their blended fair value estimate for Corteva by about $0.19 to roughly $77.95 per share, reflecting updated price targets that factor in a mixed backdrop for chemicals and agriculture but continued confidence in the company’s ability to increase earnings. Analyst Commentary Recent research on Corteva reflects a mix of optimism and caution, with price targets clustered in the mid to high US$70s and one outlier in the low US$80s.Anlatı Güncellemesi • Dec 18
CTVA: Planned Seed And Pesticide Split Will Unlock Future Earnings Power
The analyst price target for Corteva has been nudged higher by approximately $0.05 to about $77.76, as analysts factor in a slightly lower discount rate and modestly improved long term growth expectations, despite broadly cautious sector commentary and recent target reductions. Analyst Commentary Street research on Corteva reflects a divided but generally constructive view, with price targets drifting lower but ratings remaining skewed toward positive as investors reassess the company’s post breakup trajectory and near term earnings backdrop.Anlatı Güncellemesi • Dec 03
CTVA: Planned Seed And Pesticide Split Will Unlock Future Earnings Power
Our analyst price target for Corteva has been trimmed modestly in line with recent Street moves, as analysts factor in lower sector multiples and near term earnings uncertainty around the planned split, while still recognizing the company’s intact innovation engine and long term earnings growth potential. Analyst Commentary Street views on Corteva have become more bifurcated following the announced split, with valuation targets reset lower but ratings broadly supportive of the long term strategic rationale and earnings power.Analiz Makalesi • Nov 26
A Look At The Fair Value Of Corteva, Inc. (NYSE:CTVA)
Key Insights Corteva's estimated fair value is US$63.85 based on 2 Stage Free Cash Flow to Equity Current share price...Anlatı Güncellemesi • Nov 19
CTVA: Upcoming Seed And Pesticide Split Will Unlock Shareholder Value
The analyst consensus price target for Corteva has been modestly reduced, slipping from approximately $77.86 to $77.71. Analysts reflect more cautious expectations for earnings growth in light of a mixed agricultural outlook and anticipated impacts from the company's planned business split.Anlatı Güncellemesi • Nov 05
CTVA: Share Split Will Drive Shareholder Value Unlocking Amid Ongoing Business Realignment
Analysts have modestly reduced their average price target for Corteva by approximately $1.20. They cite a more cautious outlook amid challenging crop protection conditions and the company's recent announcement to split into two separate businesses.Anlatı Güncellemesi • Oct 22
Analysts Offer Mixed Views as Corteva Eyes Split and Updates Guidance Amid Modest Valuation Shift
Analysts have modestly reduced their price target for Corteva by about $0.76 to $79.05. They cite uncertainty regarding the company’s planned split and the retention of legacy liabilities, though fundamentals and growth remain largely stable.Anlatı Güncellemesi • Oct 08
High-Yield Seed Demand And Eco Policies Will Transform Agriculture
Corteva's analyst price target has been modestly reduced by $0.95 per share. Analysts cite continued uncertainty around the planned corporate split and complex crop protection market dynamics.Anlatı Güncellemesi • Sep 04
High-Yield Seed Demand And Eco Policies Will Transform Agriculture
Analysts maintained their price target for Corteva at $80.76, citing margin expansion and EBITDA growth driven by successful innovation, favorable market fundamentals, and strong execution. Analyst Commentary Ongoing cost reductions, successful innovation, and strong execution are driving margin expansion and double-digit EBITDA growth.Seeking Alpha • Apr 21
Corteva: Upgraded To Strong Buy On Tariffs, Currency Tailwinds, Strong Guidance
Summary Upgrading Corteva from Buy to Strong Buy due to macro conditions, including tariff-induced supply shocks, rising commodity prices, and currency tailwinds. Corteva's diversified supply chain and local production in seeds position it to benefit from regionalization and potential inflationary pressures in the agricultural sector. Strong Q4 earnings, record operating EBITDA margin, and robust free cash flow support the bullish outlook, with significant shareholder returns through dividends and buybacks. Improved valuation at 20x forward earnings, solid balance sheet, and technical indicators suggest potential for further upside in the current market environment. Read the full article on Seeking AlphaSeeking Alpha • Mar 30
Pure Market Inefficiency In Corteva Preferreds Pricings
Summary This article explores a market inefficiency in fixed-income securities, specifically between Corteva's $4.50 and $3.50 Series Cumulative Preferred Stocks. We identified an arbitrage opportunity due to technical buying, making it an ideal pair trade with identical issues from the same company. On 02/09/2025, we recommended CTA-B for our investment-grade long-duration portfolio. On 02/10/2025, technical high-volume buying in CTA-A turned our initial investment idea into a pair trade. This pair trade highlights how technical factors can create profitable opportunities in fixed-income securities, especially among identical issues from the same issuer. Read the full article on Seeking AlphaFinansal Durum Analizi
Kısa Vadeli Yükümlülükler: CTVA 'nin kısa vadeli varlıkları ( $16.4B ) kısa vadeli yükümlülüklerini ( $10.8B ) aşıyor.
Uzun Vadeli Yükümlülükler: CTVA şirketinin kısa vadeli varlıkları ( $16.4B ) uzun vadeli yükümlülüklerini ( $5.5B ) aşmaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: CTVA 'nin net borç/öz sermaye oranı ( 9.9% ) tatmin edici olarak değerlendirilmektedir.
Borcun Azaltılması: CTVA şirketinin borç/öz sermaye oranı son 5 yılda 6.9% seviyesinden 19.2% seviyesine yükseldi.
Borç Kapsamı: CTVA 'nin borcu işletme nakit akışı ( 24.8% ) tarafından iyi bir şekilde karşılanmaktadır.
Faiz Kapsamı: CTVA 'in borcuna ilişkin faiz ödemeleri EBIT ( 74 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.
Bilanço
Sağlıklı şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/11 15:13 |
| Gün Sonu Hisse Fiyatı | 2026/09/11 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Corteva, Inc. 34 Bu analistlerden 20, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| null null | Argus Research Company |
| Benjamin Theurer | Barclays |
| Aron Ceccarelli | Berenberg |